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Abstract 
Abnormalities of the genomic region of chromosome 19q13.2-13.4 are a common occurrence in brain malig- 
nancies and contain a possible tumor suppressor gone involved in gliomas. Since abnormalities of DNA repair 
are associated with malignancy, we assessed DNA status of the nucleotide excision repair genes located in this 
area, viz. ERCC1 and ERCC2. 
Radiodensitometry was used to assess gene copy number in samples obtained from brain tumor specimens 
from 24 patients. Nine tumors were of lower grade histology (3 pilocytic astrocytomas, 2 gangliogliomas, 4 
astrocytomas); 15 tumors were pathologiclly higher grade (4 anaplastic astrocytomas, 11 glioblastomas). Tu- 
mor samples were obtained prior to radiation or chemotherapy. Abnormalities of gene copy number of 
ERCC1 and ERCC2 were observed in 11/24 specimens (46%). Whereas increased and decreased copy num- 
bers were observed for ERCC1, only decreases in copy number of ERCC2 were seen. Three tumors (all lower 
grade) showed concurrent allelic loss of ERCC1 and ERCC2. Abnormalities of copy number for these genes 
were not associated with response to subsequent therapy nor survival. However, allelic loss of ERCC2 was 
associated with younger age at diagnosis when compared to those specimens which did not show loss. There 
were no significant differences between lower grade and higher grade tumors with respect to these investiga- 
tions. 
Abnormalities in copy number of ERCC1 and ERCC2 are common in glial tumors. Further study of this 
genomic region is necessary to define the importance of these observations in tumor pathophysiology and 
treatment. 
Introduction 
Genetic changes in tumors are frequent, and most 
likely represent a multistep pathway to the devel- 
opment of malignancy. In human gliomas, a number 
of abnormalities have been noted in a variety of dif- 
ferent chromosomal areas on both a cytogenetic 
and molecular scale, and may possibly reflect the 
inherent genomic instability of these tumors. In- 
cluded in these recurrently noted changes include 
abnormalities of chromosome 19q [1-4]. Allelic 
losses in the 19q13.2-13.4 region have been noted in 
a range of glioma subtypes, including astrocytomas, 
anaplastic astrocytomas, glioblastomas, oligoden- 
drogliomas, anaplastic oligodendrogliomas, and 
mixed gliomas [1-4]. Recent reports [4] have nar- 
rowed the common area of DNA loss to a region of 
about 8 centimorgans (5 megabases), between the 
microsatetlite markers APOC2 and HRC, includ- 
ing genes ERCC1 and ERCC2 [5]. 
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ERCC1 and ERCC2 are essential genes in the nu- 
cleotide excision repair process, and participate in 
the repair of DNA lesions such as pyrimidine dim- 
ers induced by ultraviolet light [6, 7] or interstrand 
cross links and intrastrand adducts created by che- 
motherapeutic agents such as cisplatin [8, 9]. Nucle- 
otide excision repair is considered the major path- 
way for DNA repair in mammalian cells [10]. Re- 
cently, DNA repair genes have been found to be as- 
sociated with the suppression of the tumor 
phenotype [11, 12] and hence, ERCC1 and ERCC2 
are candidate tumor suppressor genes for the area 
of deletion from 19q [1, 3]. Dabholkar et al. [13, 14] 
have shown however that increases in mRNA ex- 
pression of ERCC1 are associated with poor re- 
sponse to platinum based chemotherapy in ovarian 
tumors. As well, in vitro studies in Chinese hamster 
ovary cells have revealed increased resistance to al- 
kylating agents such as melphalan, when ERCC1 is 
overexpressed in a transfected plasmid construct 
[151. 
Human glial tumors are known to be resistant to 
a variety of DNA targeted cytotoxic chemother- 
apeutic drugs, including nitrosureas and platinum 
compounds [16]. The reasons for resistance to these 
chemotherapeutic compounds is not definitively 
known, but may be related to a variety of different 
mechanisms which include DNA repair, detoxifica- 
tion of BCNU (glutathione-S-transferase), or a 
multidrug resistant phenotype (either MDR or 
MRP) [13,16,17]. Since human gliomas show both a 
frequent loss of genetic material from chromosome 
19q13.2-13.4, and because they are resistant to a 
host of different DNA damaging therapeutic inter- 
ventions (radiation, nitrosureas, platinum based 
compounds, etc.), we felt DNA repair genes located 
in this region may be associated with tumorigenesis 
or drug resistance in these tumors. We therefore in- 
vestigated the question of gene copy number of the 
ERCC DNA repair genes in the 19q region in hu- 
man gliomas. 
Materials and methods 
D N A  preparation 
Tumors were obtained at craniotomy and frozen in 
liquid nitrogen, and transferred to a - 80 ~ C freezer 
for storage. DNA from primary tumor tissue or nor- 
mal brain was extracted by lysis, using buffer con- 
taining 20 mM Tris HC1 pH 8/10 mM EDTA/0.5% 
SDS/100 mM NaCI/10 mg proteinase K at 50-55 ~ C 
overnight. The lysate was extracted with phenol 
and chloroform and ethanol precipitated. The 
DNA pellet was washed with 70% ethanol, lyophil- 
ized, and resuspended in TE (10 mM Tris HC1 
pH 8/1 mM EDTA). All tumors were pathological- 
ly verified using a three tiered system [18]. Five gg 
of either tumor or normal brain genomic DNA was 
transferred to nylon membranes using a slot blot 
apparatus (Stratagene Inc., La Jolla, CA) according 
to the manufacturer's instructions, and crosslinked 
at 1200 Joules in a UV crosslinker (Stratagene Inc., 
La Jolla, CA). All tumor specimens were acquired 
prior to any treatment interventions. 
Probes~hybridization 
Hybridization was performed with cDNA probes 
for ERCC1 [19] and ERCC2 [20]. Control single 
copy probe pHHH163 (localizing to chromosome 
6p21) was obtained from the American Type Cul- 
ture Collection (Rockville, MD). In each case, 30- 
60 ng were labelled with [X-32p dCTP to a specificity 
of > 108 cpm/mg. Membranes were prehybridized 
with 0.6 M NaC1/8 mM EDTA/120 mM Tris HC1 
pH 7.4/0.1% sodium pyrophosphate/1% SDS/10% 
dextran sulfate/100 mg/ml salmon sperm DNA for 6 
hours, with probe subsequently being added. After 
18 hours at 42 ~ C, membranes were washed in 0.1 x 
SSC/0.1% SDS, and exposed to film for 24-48 
hours. Blots were stripped and hybridized with each 
probe two or three times and exposed to film prior 
to densitometry analysis. 
Densitometry analysis 
Resultant autoradiograms were digitized using a 
Sony SC-77 CCD camera (Cypress, CA) linked to a 
Scion LG-3 video frame grabber (Fredrick, MD) in 
a Macintosh II series computer (Cupertino, CA) as 
well as on a Molecular Dynamics Densitometer 
(Sunnyvale, CA). The former images were cap- 
tured with the program NIH-Image (version 1.55) 
as 8 bit data (256 grey scale values) and utilized as 
uncompressed TIFF files. Bands were analyzed by 
obtaining integrated density measurements with 
standardized pixel areas, and normalized to control 
calculations of single copy probes of normal human 
brain DNA. For each sample, copy number for 
ERCC1 and ERCC2 was defined as [(normalized 
integrated density value ERCC)/(normalized inte- 
grated density value pHHH163)]. Ratios _> 2 for 
each tumor specimen were considered an increase 
in copy number; decreases in copy number were de- 
fined similarly with a value < 0.5. 
Patient data 
Patient data was obtained from the medical records 
of the treating hospitals. Information regarding age, 
sex, pathologic grade of tumor, number and type of 
chemotherapeutic interventions and time to death 
were obtained. 
Statistics 
Single pairwise comparisons were performed using 
a Student's t-test function, with multiple pairwise 
comparisons corrected with either the Bonferroni 
Table 1. Patient characteristics 
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or Tukey modifications. Significant difference was 
assumed with a p _ 0.05. Two sided p values are re- 
ported. 
Results 
Tumor histology~patient characteristics 
Table 1 shows the histology and patient character- 
istics of the unselected study population. Pilocytic 
astrocytomas [3] and gangliogliomas [2] were com- 
bined and labelled low grade [5]. Four tumors were 
graded as astrocytoma, four as anaplastic astrocyto- 
ma, and 11 as glioblastoma. One tumor in the glio- 
blastoma group was initially diagnosed as an oligo- 
dendroglioma, but upon re-resection (and whence 
tissue DNA was obtained) was found to be path- 
ologically a glioblastoma. This patient received no 
interval treatment except surgery. 
Copy number changes 
Figure 1 depicts the results of the slot blot autora- 
diograms of ERCC1 and ERCC2 grouped by tumor 
histology, as compared to the single copy probe 
pHHH163. Table 2 shows the results of the copy 
number changes by histologic tumor grade. Densi- 
tometric measurements revealed allelic losses of 
ERCC1 in four cases (4/24, 17%). Losses were 
noted in 1/5 (20%) low grade tumors, 2/4 (50%) as- 
trocytomas, and 1/11 (9%) glioblastomas. None of 
the anaplastic astrocytomas showed evidence of al- 
lelic loss. Increase in copy number of ERCC1 was 
seen in four tumors (4/24, 17%). The range of copy 
number increase by integrated density measure- 
Histology Median age (range) Male Female 
Low grade 17 (7-31) 3 2 
Astrocytoma 35 (24-42) 1 3 
Anaplastic 34 (28-53) 2 2 
astrocytoma 
Glioblastoma 57 (22-75) 7 4 




Fig. 1. Results of DNA slot blots of glial tumors probed with pHHH163, ERCC1 and ERCC2. Column A shows the normal brain control 
used for each blot. Panel A. Low grade tumors. ERCC1 showed allelic loss in one tumor (sample C) and increased copy number in one 
tumor (samples D). ERCC2 revealed allelic loss in two tumors (samples B and C); note concurrent loss of ERCC1 and ERCC2 in sample 
C. Panel B. Astrocytoma. ERCC1 and ERCC2 were noted to be lost concurrently in two samples (B and E). No increases in copy number 
of either gene were noted. Panel C. Anaplastic astrocytoma. Increases in copy number of ERCC1 were seen in samples B amd D. No 
allelic loss was noted of either gene in anaplastic astrocytoma. Panel D. Glioblastoma. Increased copy number of ERCC1 was noted in one 
specimen (sample F) with loss noted in one (sample K), ERCC2 showed loss in samples G and L. 
ments in these tumors was 2-4.1. In contrast to the 
ERCC1 allelic loss results, 2/4 (50%) of anaplastic 
astrocytomas showed increases in copy number. In 
addition, 1/5 (20%) low grades revealed an increase 
in copy number, with 1/11 (9 %) glioblastomas show- 
ing a copy number increase. 
No tumors revealed increases in copy number of 
ERCC2. No concomitant loss of ERCC2 was noted 
with the presence of increase in copy number of 
ERCC1. Deletions of ERCC2 were noted in six tu- 
mors (6/24, 25%). Of the low grade tumors, 2/5 
(40%) showed allelic loss; one of these also re- 
vealed loss of ERCC1. Both astrocytoma tumors 
which showed loss of ERCC1 also had allelic loss of 
ERCC2 (2/4, 50%). As noted for ERCC1, no ana- 
plastic astrocytoma was found to harbor loss of 
ERCC2. Finally, 2/11 (18%) glioblastomas showed 




As a group, median age at diagnosis was not differ- 
ent between the patients with increases in copy 
number of ERCC1 (median 37.5 years, n = 4) and 
those who did not (median 32 years, n = 20, p 
> 0.90). Similarly, age differences were not noted 
between the subgroups which had allelic loss of 
ERCC1 (median 35 years, n = 4) and those who did 
not (median 35 years, n = 2, p > 0.80). Finally, a non- 
significant trend with respect to age was seen in 
those patients with loss of ERCC2 (median 29.5 
years, n = 6) compared to those without loss 
(median 40, n = 18, p = 0.10). 
Chemotherapy~survival 
Table 3 shows the data correlating ERCC status and 
clinical outcome in the 15 patients with higher grade 
gliomas (anaplastic astrocytoma and glioblastoma). 
The primary chemotherapeutic agent administered 
to these patients were the nitrosoureas, although 
procarbazine and vincristine were also given, either 
alone or separately. No significant difference in sur- 
vival or number of courses of chemotherapy admin- 
istered was noted between the patients who had no 
change in ERCC1 and ERCC2 status versus those 
who showed increases in copy number of allelic 
loss. Stratifying the results with and without the 
anaplastic astrocytoma patient data did not alter 
the results. 
Table 2. Tumor histology and ERCC status 
Histology Increase ERCC1 (%) Decrease ERCC1 (%) Decrease ERCC1 (%) Total# changes 
(%) 
Low grade 1/5 (20) 1/5 (20) 2/5 (40) 3/5 (60) 1 
Astrocytoma 0/4 (0) 2/4 (50) 2/4 (50) 2/4 (50) 2 
Anaplastic 2/4 (50) 0/4 (0) 0/4 (0) 2/4 (50) 
astrocytoma 
Glioblastoma 1/11 (9) 1/11 (9) 2/11 (18) 4/11 (37) 
Total 4/24 (17) 4/24 (17) 6/24 (25) 11/24 (46) 
1 A ganglioglioma showed allelic loss of both ERCCI and ERCC2. 
2 Both tumors showed allelic loss of ERCC1 and ERCC2. 
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Discussion 
DNA repair is important in the genesis of a number 
of malignancies, including those associated with 
Xeroderma pigmentosum [21, 22], ataxia telangiec- 
tasia [23, 24], human non-polyposis colon cancer 
[11] and possibly other human cancers [25]. Where- 
as O6-alkylguanine DNA methyltransferase has 
been associated with chemotherapeutic resistance 
in gliomas [16], the association of specific abnormal- 
ities of DNA repair genes has not been previously 
associated with this disease. In this report, we docu- 
ment abnormalities of DNA gene copy number for 
the human nucleotide excision repair genes ERCC1 
and ERCC2, which occur in up to 46% of tumor 
samples prior to either radiation or chemother- 
apeutic intervention. 
Abnormalities of the region of chromosome 
19q13 have been associated with a variety of brain 
tumors of glial origin in several recent reports [1-4]. 
Loss of heterozygosity has been noted in the 
19q13.2-13.4 region using minisatellite and other 
polymorphic probes [1-4]. The common area of de- 
letion spans a region of about 8 centimorgans, and 
includes genes APOC2, ERCC2, ERCC1, DNA li- 
gase I, DM and HRC [4, 5]. The changes reported in 
brain tumor specimens are variable, and appear to 
differ in different tumor subtypes. However, this is 
the first report of increases as well as decreases in 
gene copy number, for one or more genes in this 
region. The changes noted in our specimens may re- 
flect the inherent genomic instability of the tumors, 
or may be related to this region being particularly 
affected subsequent to tumor development. Fur- 
ther studies will be necessary to define the role (if 
any) of these copy number changes on glial tumori- 
genesis. 
mRNA expression of ERCC1 and ERCC2 has 
been studied in human glioma and ovarian tumor 
specimens by this group [13,14, 26]. In patients with 
gliomas, matched malignant and non-malignant tis- 
sues were studied for mRNA expression of these 
two genes. Excellent concordance of expression of 
these two genes was seen in normal non-malignant 
tissues; however, disordered expression of the two 
genes was noted in malignant tissues [26]. We be- 
lieve a reason for disordered expression at the 
mRNA level in malignant brain tissues may be re- 
lated to copy number abnormalities of genomic 
DNA for these two genes. In human ovarian cancer, 
disordered expression of ERCC1 and ERCC2 has 
also been observed [13, 14], and studies of DNA 
copy number are in progress. Further studies will be 
needed correlating copy number changes and 
mRNA and protein expression to substantiate this 
hypothesis. 
Increased mRNA expression of ERCC1 is associ- 
ated with clinical resistance to DNA damaging che- 
motherapy in human ovarian cancer [13, 14], and 
such studies are in progress in human malignant 
gliomas in this laboratory. The current study did not 
show a direct relationship between DNA copy 
number for ERCC1 and clinical outcome in this dis- 
ease. This may possibly reflect a lesser role of these 
genes in resistance to the nitrosoureas such as 
BCNU, or the result of the small sample size stud- 
ied. Nevertheless, we believe additional studies of 
DNA repair genes are warranted in neoplasms of 
the brain and ovary, as well as other malignancies 
where DNA damaging therapy is frequently em- 
ployed. 
Table 3. ERCC status and clinical outcome in anaplastic astrocytoma and gliob|astoma 





Abnormal ERCC1/2 6 4 (0-8) 
copy number 
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